Tech Company Financing Transactions
Aminex Therapeutics Funding Round
Aminex Therapeutics closed a $4 million Series A funding round on 11/11/2015. Backers included private investors.
Transaction Overview
Company Name
Announced On
11/11/2015
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Series A
Investors
Proceeds Purpose
The proceeds will be used to finalize Aminex's preclinical testing and prepare for Phase 1/2A human clinical trials to start midyear 2016. Our patented AMX-513 combination therapy enables the immune system to attack cancer by regulating myeloid-derived suppressor cells.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11335 NE 122nd Way 105
Kirkland, WA 98034
USA
Kirkland, WA 98034
USA
Phone
Website
Email Address
Not Recorded
Overview
Aminex Therapeutics, Inc., is a drug development company focused on discovery, development, and commercialization of a new subclass of cancer immunotherapies known as suppressor cell modulators (SCMs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jim Skaggs
Chief Operating Officer
Tom Graham
Chief Scientific Officer
Mark Burns
Vice President
Michael Palfreyman
Browse more venture capital transactions:
Prev: 11/11/2015: EventBoard venture capital transaction
Next: 11/11/2015: CircleUp venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. All VC database entries on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs